s_150324_7c
EPN · Posterior Fossa EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Posterior Fossa EPN
- cancer_type
- EPN
- subtype
- Posterior Fossa EPN
- e1_e2
- E2
- umap1_2d
- -6.381700103
- umap2_2d
- 0.396976534
- umap1_3d
- 0.776876351
- umap2_3d
- 4.338808144
- umap3_3d
- 0.198389003
- dataset
- EPN-Heidelberg
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.480
- OXIDATIVE_PHOSPHORYLATION+0.440
- PROTEIN_SECRETION+0.370
- HEME_METABOLISM+0.350
- ADIPOGENESIS+0.320
- FATTY_ACID_METABOLISM+0.320
- TGF_BETA_SIGNALING+0.230
- XENOBIOTIC_METABOLISM+0.230
- PEROXISOME+0.220
- ANDROGEN_RESPONSE+0.200
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.430
- G2M_CHECKPOINT-0.380
- E2F_TARGETS-0.370
- ANGIOGENESIS-0.330
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.310
- HEDGEHOG_SIGNALING-0.310
- KRAS_SIGNALING_DN-0.300
- APICAL_SURFACE-0.280
- MYC_TARGETS_V2-0.270
- APICAL_JUNCTION-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | s_150324_8c | EPN | Posterior Fossa EPN | 0.986 |
| 2 | SJEPD030908_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.783 |
| 3 | BS_KVNGNETA | Med | Medulloblastoma | 0.754 |
| 4 | TCGA-A8-A099-01A-11R-A00Z-07 | — | B | 0.750 |
| 5 | BS_N210XMKR | low-grade glioma | — | 0.748 |
| 6 | SRR6013501 | — | cohortA1 | 0.747 |
| 7 | MNG1214 | — | — | 0.747 |
| 8 | BS_WYERXS4G | Supratentorial Ependymoma | — | 0.731 |
| 9 | TCGA-75-5146-01A-01R-1628-07 | — | cohortA1 | 0.726 |
| 10 | MDT-AP-0397 | Med | Medulloblastoma | 0.725 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.480 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.440 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.370 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.350 | Temsirolimus | — uncovered |
| ADIPOGENESIS | 0.320 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.320 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.230 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.230 | Inavolisib | — uncovered |
| PEROXISOME | 0.220 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| APOPTOSIS | 0.140 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.140 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.130 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.120 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.110 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.070 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.060 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.050 | Idelalisib | — uncovered |